Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones

Journal of Molecular Endocrinology

Volumn 49, Issue 2, 2012, Pages 69-78

  Yu, Run ^a   Chen, Chun Rong ^a   Liu, Xiaohong ^b   Kodra, János T ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b GILEAD SCIENCES   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; CHAPERONE; CURCUMIN; CYCLIC AMP; ENHANCED GREEN FLUORESCENT PROTEIN; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; L 168049; PROLINE; SERINE; THAPSIGARGIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENDOPLASMIC RETICULUM STRESS; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; GENE MUTATION; HUMAN; HUMAN CELL; HYPERGLUCAGONEMIA; INCUBATION TIME; INTERNALIZATION; LIPOPHILICITY; MAHVASH DISEASE; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; MUTANT; OSMOSIS; PANCREAS ISLET CELL HYPERPLASIA; PANCREATIC NEUROENDOCRINE TUMOR; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; WESTERN BLOTTING;

ALANINE; ASPARAGINE; CELL MEMBRANE; CURCUMIN; CYCLIC AMP; DRUG DESIGN; GLUCAGON; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; MOLECULAR CHAPERONES; MUTATION; PANCREATIC NEOPLASMS; PROTEIN TRANSPORT; PYRIDINES; PYRROLES; RECEPTORS, GLUCAGON; SERINE; THAPSIGARGIN;

EID: 84866366620     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0051     Document Type: Article

References (35)

1. Authier F & Desbuquois B 2008 Glucagon receptors. Cellular and Molecular Life Sciences 65 1880-1899. (doi:10.1007/s00018-008-7479-6)
2. Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG & Bouvier M 2004 Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Molecular Endocrinology 18 2074-2084. (doi:10.1210/me.2004-0080)
3. Conn PM, Ulloa-Aguirre A, Ito J & Janovick JA 2007 G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacological Reviews 59 225-250. (doi:10.1124/pr.59.3.2)
4. Costanzi S, Joshi BV, Maddileti S, Mamedova L, Gonzalez-Moa MJ, Marquez VE, Harden TK & Jacobson KA 2005 Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. Journal of Medicinal Chemistry 48 8108-8111. (doi:10.1021/jm050911p)
5. Cryer PE 2011 Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153 1039-1048. (doi:10.1210/en.2011-1499)
6. Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N & Kjaer A 2009 Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library. Biopolymers 91 201-206. (doi:10.1002/bip.21117)
7. Durdagi S, Supuran CT, Strom TA, Doostdar N, Kumar MK, Barron AR, Mavromoustakos T & Papadopoulos MG 2009 In silico drug screening approach for the design of magic bullets: a successful example with anti-HIV fullerene derivatized amino acids. Journal of Chemical Information and Modeling 49 1139-1143. (doi:10.1021/ci900047s)
8. Filipeanu CM, de Vries R, Danser AH & Kapusta DR 2011 Modulation of a(2C) adrenergic receptor temperature-sensitive trafficking by HSP90. Biochimica et Biophysica Acta 1813 346-357. (doi:10.1016/j. bbamcr.2010.11.020)
9. Furuta M, Yano H, Zhou A, Rouillé Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H & Steiner DF 1997 Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. PNAS 94 6646-6651. (doi:10.1073/pnas.94.13.6646)
10. Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V et al. 2009 Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible a-cell hyperplasia and hyperglucagonemia. Journal of Pharmacology and Experimental Therapeutics 331 871-881. (doi:10.1124/jpet.109.157685)
11. Janovick JA, Maya-Nunez G & Conn PM 2002 Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specificprotein-folding template:misrouted proteins as a novel disease etiology and therapeutic target. Journal of Clinical Endocrinology andMetabolism87 3255-3262. (doi:10.1210/jc.87.7.3255)
12. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG & Conn PM 2003 Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. Journal of Pharmacology and Experimental Therapeutics 305 608-614. (doi:10.1124/jpet.102.048454)
13. Janovick JA, Park BS & Conn PM 2011 Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs. PLoS ONE 6 e22784. (doi:10.1371/journal.pone.0022784)
14. Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Méjean C, Morin D, Loison S, Bonnet D, Hibert M, Mouillac B et al. 2009 Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology 20 2190-2203. (doi:10.1681/ASN.2008121289)
15. Kodra JT, Jørgensen AS, Andersen B, Behrens C, Brand CL, Christensen IT, Guldbrandt M, Jeppesen CB, Knudsen LB, Madsen P et al. 2008 Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. Journal of Medicinal Chemistry 51 5387-5396. (doi:10.1021/jm7015599)
16. Michalak M, Groenendyk J, Szabo E, Gold LI & Opas M 2009 Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochemical Journal 417 651-666. (doi:10.1042/BJ20081847)
17. Oueslati M, Hermosilla R, Schönenberger E, Oorschot V, Beyermann M, Wiesner B, Schmidt A, Klumperman J, Rosenthal W & Schülein R 2007 Rescue of a nephrogenic diabetes insipiduscausing vasopressin V2 receptor mutant by cell-penetrating peptides. Journal of Biological Chemistry 282 20676-20685. (doi:10.1074/jbc.M611530200)
18. Ouyang D, Dhall D & Yu R 2011 Pathologic pancreatic endocrine cell hyperplasia. World Journal of Gastroenterology 17 137-143. (doi:10.3748/wjg.v17.i2.137)
19. Petersen KF & Sullivan JT 2001 Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44 2018-2024. (doi:10.1007/s001250100006)
20. Quesada I, Tudurí E, Ripoll C & Nadal A 2008 Physiology of the pancreatic a-cell and glucagon secretion: role in glucose homeostasis and diabetes. Journal of Endocrinology 199 5-19. (doi:10.1677/JOE-08-0290)
21. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, Ding VD, Li Z, Bansal A, Miller C, Cohen SM et al. 2004 A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53 3267-3273. (doi:10.2337/diabetes.53.12.3267)
22. Robben JH, Sze M, Knoers NV & Deen PM 2006 Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Molecular Biology of the Cell 17 379-386. (doi:10.1091/mbc.E05-06-0579)
23. Runge S, Thøgersen H, Madsen K, Lau J & Rudolph R 2008 Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. Journal of Biological Chemistry 283 11340-11347. (doi:10.1074/jbc.M708740200)
24. Spiegel AM & Weinstein LS 2004 Inherited diseases involving G proteins and G protein-coupled receptors. Annual Review of Medicine 55 27-39. (doi:10.1146/annurev.med.55.091902.103843)
25. Tao YX 2006 Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacology and Therapeutics 111 949-973. (doi:10.1016/j.pharmthera.2006.02.008)
26. Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R & Reedtz-Runge S 2010 Crystal structure of glucagonlike peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. Journal of Biological Chemistry 285 723-730. (doi:10.1074/jbc.M109.033829)
27. Unson CG, Cypess AM, Kim HN, Goldsmith PK, Carruthers CJ, Merrifield RB & Sakmar TP 1995 Characterization of deletion and truncation mutants of the rat glucagon receptor. Seven transmembrane segments are necessary for receptor transport to the plasma membrane and glucagon binding. Journal of Biological Chemistry 270 27720-27727. (doi:10.1074/jbc.270.46.27720)
28. Unson CG, Wu CR, Jiang Y, Yoo B, Cheung C, Sakmar TP & Merrifield RB 2002 Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling. Biochemistry 41 11795-11803. (doi:10.1021/bi025711j)
29. Webb GC, Akbar MS, Zhao C, Swift HH & Steiner DF 2002 Glucagon replacement via micro-osmotic pump corrects hypoglycemia and a-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51 398-405. (doi:10.2337/diabetes.51.2.398)
30. Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E & Ahrén B 2007 Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50 1453-1462. (doi:10.1007/s00125-007-0675-3)
31. Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ et al. 2009 Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. Journal of Pharmacology and Experimental Therapeutics 329 102-111. (doi:10.1124/jpet.108.147009)
32. Yu R, Nissen NN, Dhall D & Heaney AP 2008 Nesidioblastosis and hyperplasia of a cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. Pancreas 36 428-431. (doi:10.1097/MPA. 0b013e31815ceb23)
33. Yu R, Wawrowsky K & Zhou C 2011a A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinology and Nutrition 58 258-266. (doi:10.1016/j.endonu.2011.04.002)
34. Yu R, Dhall D, Nissen NN, Zhou C & Ren SG 2011b Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS ONE 6 e23397. (doi:10.1371/journal.pone.0023397)
35. Zhou C, Dhall D, Nissen NN, Chen CR & Yu R 2009 Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, a cell hyperplasia, and islet cell tumor. Pancreas 38 941-946. (doi:10.1097/MPA.0b013e3181b2bb03)